Skip to content

Effect of Unani drug (shoniz with sirka) on Buthur labanniya (Acne vulgaris)

â??Clinical Study of Buthur Labaniyya (Acne Vulgaris) With Therapeutic Evaluation of Topical Unani Drug, Shoniz (Nigella sativa) and Sirka (vinegar) in its Management.â??

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025718
Enrollment
60
Registered
2020-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: Paste of shoniz and sitka (Topical application): Ingredients: Shoniz and Sirka. Method of preparation: Paste of Shoniz and Sirka will be prepared as per standard procedure. Dosage and d

Sponsors

Central Council for Research in Unani MedicineNew Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Clinically stable patients of Buthur labanniya 2.Patients having comedones,papules,pustules,itching and erythema 3.Patients willing to give consent 4.Patients irrespective of gender 5.Patients in the age group of 10 to 40 years

Exclusion criteria

Exclusion criteria: 1.Patients below the age of 10 and above the age of 40 2.Pregnant females 3.Lactating mothers 4.Mentally retarded persons 5.Patients with severe acne 6.Patients on corticosteroid therapy,anticonvulsant therapy or taking oral contraceptives 7.Patients suffering from other concomitant diseases like acne rosacea,acne fulminans,acne necrotica,psoriasis or eczema etc 8.Patients diagnosed of PCOS 9.Patients with diabetes mellitus,chronic kidney disease and chronic liver disease 10.Patients with thyroid disease 11.History of allergy to Benzoyl Peroxide 13.Patients who fail to give consent 14.Patients who have used any anti acne treatment in last 30 days

Design outcomes

Primary

MeasureTime frame
Relief in signs and symptoms of acne vulgaris (Buthur labanniya)Timepoint: 2 to 8 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safetyTimepoint: 2 to 8 weeks

Countries

India

Contacts

Public ContactDr Shameem Ahmed Rather

Regional Research Institute of Unani Medicine

naquibislam@gmail.com9469154930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026